
- Oncology NEWS International Vol 15 No 8
- Volume 15
- Issue 8
IOM Panel Says Asbestos Exposure Can Cause Cancer of the Larynx
There is sufficient evidence to show that asbestos exposure can cause cancer of the larynx.
WASHINGTONThere is sufficient evidence to show that asbestos exposure can cause cancer of the larynx, according to a new report from the Institute of Medicine (IOM). However, evidence that such exposure may cause cancers of the pharynx, stomach, colon, and rectum, while suggestive, is "ultimately insufficient" to link asbestos to those diseases, and the evidence remains inadequate to reach any conclusion about this group of minerals as a cause of esophageal cancer, the IOM said.
Asbestos is a well-established cause of lung cancer and mesothelioma. However, its potential role in a number of cancers of the respiratory tract and digestive system has remained an issue. Members of Congress who are addressing the issue of compensation for people with asbestos-related diseases sought a more definitive assessment.
Based on a review of 18 case-control, 35 epidemiologic, and a number of animal studies, an IOM panel decided that the consistency of the epidemiologic studies, as well as several biological mechanisms supporting the plausibility that asbestos could cause the cancer, outweighed the lack of confirmatory evidence from animal studies or documentation that the mineral fibers persist in the larynx. "The committee concluded that the evidence is sufficient to infer a causal relationship between asbestos exposure and laryngeal cancer," according to the report, Asbestos: Selected Cancers.
Articles in this issue
about 19 years ago
Younger Age at Brain Tumor Diagnosis Portends Poor Emotional Outcomeabout 19 years ago
Higher Responses in Metastatic Colon Ca When Cetuximab Added to Chemoabout 19 years ago
Triple Targeted Therapy Is Tested in Pts With Solid Tumorsabout 19 years ago
FDA Approves Three-Drug Combination Tablet for HIV-1about 19 years ago
Side Effects Persist 16 Years After Prostate Ca Brachytherapyabout 19 years ago
No Significant QOL Differences for Raloxifene and Tamoxifenabout 19 years ago
Amrubicin Appears Promising in Small-Cell Lung Cancerabout 19 years ago
R-MP Active in Older Pts With Newly Diagnosed Myelomaabout 19 years ago
Sunitinib and Sorafenib Active in Phase II Advanced NSCLC Trialsabout 19 years ago
Takeda Signs Agreement With Galaxy Biotech for HuL2G7Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.



















































































